SCHEMBL6324202

SCHEMBL6324202

COc1ccc(-c2cccc3c2/C(=C/c2[nH]c(C)c(C(=O)O)c2C)C(=O)N3)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.60
KDR P35968 11/20 0.60
FLT4 P35916 4/20 0.60
KIT P10721 2/20 0.60
PDGFRB P09619 8/20 0.58
AURKB Q96GD4 6/20 0.58
AURKA O14965 2/20 0.58
AURKC Q9UQB9 2/20 0.58
MET P08581 1/20 0.58
ALK Q9UM73 2/20 0.52
FGFR1 P11362 6/20 0.52
RET P07949 2/20 0.52
ABL1 P00519 1/20 0.52
EGFR P00533 2/20 0.49
LRRK2 Q5S007 1/20 0.47
PDGFRA P16234 1/20 0.45
GAK O14976 1/20 0.45
RPS6KA5 O75582 1/20 0.45
RPS6KA4 O75676 1/20 0.45
LATS1 O95835 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324208 1.00 FLT3 (0.60) FLT3KDRFLT4KITPDGFRB
SCHEMBL6319851 0.91 KDR (0.56) FLT3KDRFLT4KITPDGFRB
SCHEMBL6319847 0.91 KDR (0.56) FLT3KDRFLT4KITPDGFRB
SCHEMBL16090378 0.90 ALK (0.56) FLT3KDRFLT4KITPDGFRB
SCHEMBL6321989 0.90 ALK (0.58) FLT3KDRFLT4KITPDGFRB
SCHEMBL6321986 0.90 ALK (0.58) FLT3KDRFLT4KITPDGFRB
SCHEMBL6320435 0.89 ALK (0.52) FLT3KDRFLT4KITPDGFRB
SCHEMBL6320440 0.89 ALK (0.52) FLT3KDRFLT4KITPDGFRB
SCHEMBL6320314 0.88 ALK (0.54) FLT3KDRFLT4KITPDGFRB
SCHEMBL6321012 0.88 ALK (0.65) FLT3KDRFLT4KITPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 FLT3 596/4885KDR 819/4885FLT4 1227/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 FLT3 596/4885KDR 819/4885FLT4 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.